epirubicin has been researched along with Vomiting in 68 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (14.71) | 18.7374 |
| 1990's | 30 (44.12) | 18.2507 |
| 2000's | 14 (20.59) | 29.6817 |
| 2010's | 11 (16.18) | 24.3611 |
| 2020's | 3 (4.41) | 2.80 |
| Authors | Studies |
|---|---|
| Iseki, K; Kobayashi, M; Nakai, M; Ogawa, K; Saito, Y; Sakamoto, T; Sugawara, M; Takekuma, Y; Yamada, T | 1 |
| Cao, J; Hu, X; Ouyang, Q; Ragaz, J; Shao, Z; Teng, Y; Wang, B; Wang, L; Wang, S; Wang, X; Wang, Z; Wu, J; Zhang, J | 1 |
| Aogi, K; Baba, M; Chiba, Y; Fujiwara, K; Hirano, G; Imamura, CK; Imoto, S; Matsumoto, K; Matsuura, K; Miyazaki, C; Naito, Y; Osaki, A; Saeki, T; Sato, K; Takahashi, M; Takano, T; Tamura, K; Tokunaga, S; Yanagihara, K | 1 |
| An, Y; Chen, T; Chen, Y; Dong, Y; Fu, L; Jin, B; Jin, F; Jin, X; Liu, J; Liu, Y; Luo, Y; Man, L; Qu, J; Qu, X; Shi, J; Sun, T; Teng, Y; Teng, Z; Wang, J; Wang, Z; Wen, F; Xie, X; Yu, P; Yuan, C; Zhang, J; Zhang, L; Zhang, X; Zhao, M; Zhou, L; Zhu, Z | 1 |
| Gourd, E | 1 |
| Araz, M; Artac, M; Beypinar, I; Inci, F; Karaagac, M; Koral, L; Korkmaz, L; Uysal, M | 1 |
| Cardillo, FD; Cognetti, F; Evangelista, S; Fabi, A; Fattoruso, SI; Pacetti, U; Veltri, E | 1 |
| da Silva, PR; de Almeida, AM; Gozzo, Tde O; Moysés, AM | 1 |
| Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y | 1 |
| Ichiba, Y; Kajiume, S; Kameda, K; Kiba, T; Kimoto, S; Morii, N; Ogawa, Y; Okada, Y; Takahashi, H; Yamashiro, H | 1 |
| Imoto, S; Isaka, H; Kawakami, H; Nagai, S; Nomura, H; Shinohara, T | 1 |
| Cai, RG; Li, Q; Wang, JY; Wu, WH; Xu, BH; Yuan, P; Zhang, P; Zhao, LM; Zhou, AP | 1 |
| de Camargo, B; del Giglio, A; Lajolo, PP | 1 |
| Futamura, M; Itoh, Y; Kawaguchi, Y; Kawahara, K; Kitaichi, K; Matsuura, K; Nawa, M; Nishigaki, M; Nishimura, M; Tsukioka, T; Yoshida, K | 1 |
| Arai, T; Fujii, C; Fujino, M; Furukawa, H; Hachino, Y; Hamaguchi, Y; Iseki, C; Kamigaki, S; Kanai, Y; Nakamura, Y; Oshiro, C | 1 |
| Fan, Y; Li, Q; Ma, F; Wang, JY; Wang, WM; Xu, BH; Yuan, P; Zhang, P | 1 |
| Eksborg, S; Lönnqvist, PA; Öbrink, E; Oddby-Muhrbeck, E; Rotstein, S | 1 |
| Corral, N; Esteban, E; Estrada, E; Fernández, Y; Fra, J; González de Sande, L; Lacave, AJ; Modollel, A; Muñiz, I; Palacio, I; Sala, M; Vieitez, JM | 1 |
| Maruyama, S | 1 |
| Chen, Z; Feng, YL; Li, B; Ling, CQ; Yu, CQ; Zhu, DZ | 1 |
| Bohidar, N; Eisenberg, PD; Gabriel, M; Gralla, RJ; Grunberg, SM; Herrstedt, J; Hesketh, PJ; Horgan, KJ; Hustad, CM; Klinger, G; Muss, HB; Raftopoulos, H; Rodgers, A; Skobieranda, F; Warr, DG | 1 |
| Bang, YJ; Ham, HS; Hong, YS; Im, SA; Im, YH; Kim, KW; Kim, SB; Kim, TY; Kim, WK; Lee, J; Lee, KE; Lee, KH; Lee, MA; Lee, MH; Lee, NS; Lee, SN; Park, HS; Park, YH; Seo, JH; Song, HS | 1 |
| Abali, H; Guler, N; Oyan, B | 1 |
| Antimi, M; Antonuzzo, L; Arcangeli, A; Banducci, S; Bellini, V; Biagioni, F; Bianchini, D; Bilancia, D; Bisagni, G; Biscottini, B; Boni, C; Bracci, R; Bravi, S; Bruno, L; Cabassi, A; Camera, S; Camisa, R; Canaletti, R; Carboni, M; Carlini, P; Carroccio, R; Cascinu, S; Catalano, G; Catalano, V; Cavalli, C; Cesari, M; Cognetti, F; Contu, A; Corgna, E; Cortesi, E; Croce, E; Dalla Mola, A; De Filippis, S; De Stefanis, M; Di Costanzo, F; Dinota, A; Enzo, MR; Farris, A; Figoli, F; Floriani, I; Foa, P; Fornarini, G; Francavilla, F; Frignano, M; Gasperoni, S; Gilli, G; Giunta, A; Grigniani, F; Ionta, MT; Italia, M; Labianca, R; Lastraioli, E; Leoni, M; Lungarotti, F; Luppi, G; Manzione, L; Masoni, L; Massidda, B; Mela, M; Messerini, L; Monzio Compagnoni, B; Muscogiuri, A; Natalini, G; Nelli, F; Nicolosi, A; Oldani, S; Olgiati, A; Olivetti, A; Orselli, G; Pandolfi, U; Papiani, G; Pazzola, A; Piga, A; Pisani Leretti, A; Porrozzi, S; Recchia, F; Romiti, A; Rondini, E; Rossetti, R; Rovei, R; Saggese, M; Sarobba, MG; Scipioni, L; Strafiuso, G; Tomao, S; Tonato, M; Torri, V; Trignano, M; Zironi, S | 1 |
| Bani, MR; Beckmann, MW; Engel, J; Fasching, PA; Kollmannsberger, B; Kreis, H; Lausen, B; Lux, MP; Niesler, B; Strick, R; Strissel, PL; Weihbrecht, S | 1 |
| Hao, XM; Hui, R; Zhang, J; Zhang, M | 1 |
| Bramwell, V; Bruntsch, U; Cavalli, F; Decoster, G; Dombernowsky, P; Høst, H; Renard, G; Rozencweig, M; ten Bokkel Huinink, W; Van Glabbeke, M | 1 |
| Hayashi, K; Kitamura, M; Kosaki, G; Takahashi, I; Tominaga, T | 1 |
| Kemeny, N; Michaelson, R; Young, C | 1 |
| Bonadonna, G; Bonfante, V; Villani, F | 1 |
| Akesson, M; Andersson, H; Friberg, LG; Horvath, G; Johansson, O; Westberg, R | 1 |
| Adenis, A; Bonneterre, J; Hebbar, M; Hecquet, B; Lecomte, S; Pion, JM; Vanlemmens, L | 1 |
| Ang, PT; Khoo, KS; Tan, EH | 1 |
| Basser, RL; Cebon, J; Duggan, G; Green, MD; Mihaly, G; Rosenthal, MA; Sobol, MM | 1 |
| Kitada, M; Sawaragi, I | 1 |
| Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM | 1 |
| Stewart, A | 1 |
| Barrenetxea, G; Centeno, MM; de la Rica, M; Rodríguez-Escudero, FJ; Romero, H; Schneider, J | 1 |
| Ionta, MT; Massidda, B | 1 |
| du Bois, A; Holy, R; Kriesinger-Schröder, H; Vach, W | 1 |
| Cannata, G; Gebbia, N; Gebbia, V; Testa, A | 1 |
| Fukui, H; Hoshino, K; Ikeda, M; Kawaguchi, H; Kimura, O; Ono, K | 1 |
| Baù, MG; Berruti, A; Bottini, A; Buniva, T; Danese, S; Dogliotti, L; Farris, A; Moro, G; Porcile, G; Richiardi, G; Zola, P | 1 |
| Fujimori, R; Sanada, H; Sekine, M; Serikawa, T; Shichiri, K; Tanaka, K | 1 |
| Athanassiadis, A; Damigos, D; Fountzilas, G; Giannakakis, T; Nicolaides, C; Pavlidis, N; Skarlos, D | 1 |
| Abe, T; Hashimoto, Y; Kojima, A; Mori, M; Nagamine, T; Sohara, N; Takagi, H; Takahashi, H | 1 |
| Andersen, LJ; Dombernowsky, P; Havsteen, H; Herrstedt, J; Kjaer, M; Kjaerbøl, AG; Langer, SW; Lund, H; Sigsgaard, T | 1 |
| Hojo, S; Noguchi, S; Shiba, E; Taguchi, T; Takamura, Y; Tsukamoto, F; Watanabe, T; Yoneda, K | 1 |
| Bauduer, F; Coiffier, B; Desablens, B | 1 |
| Cognetti, F; Gamucci, T; Nardi, M; Serrone, L; Zeuli, M | 1 |
| Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Kouroussis, C; Retalis, G; Sivridis, E | 1 |
| Benjachai, W; Cheirsilpa, A; Kosiyatrakul, T; Puriphat, S; Tangkrutt, S | 1 |
| Armas, A; Asins Codoner, J; Calero, F; Iglesias, J; Jimeno, J; Mendana, J; Murillo, F; Rementería, A; Rodríguez-Escudero, F; Ugalde, F | 1 |
| Dicato, MA | 1 |
| Bastit, P; Bonneterre, J; Cappelaere, P; Chevrier, A; Fargeot, P; Geyer, G; Kerbrat, P; Metz, R; Roche, H; Tubiana-Hulin, M | 1 |
| Adler, M; Christmann, D; Fenzl, E; Marschner, NW; Nagel, GA; Upadhyaya, B | 1 |
| Angeletti, CA; Basolo, F; Bruno, J; Hardin, M; Macchiarini, P | 1 |
| Carmo-Pereira, J; Costa, FO; Henriques, E; Miles, DW; Richards, MA; Rubens, RD | 1 |
| Baldini, E; Bruzzi, P; Campora, E; Chiara, S; Rosso, R; Rubagotti, A; Sertoli, MR | 1 |
| Bonneterre, J; Bons, J; Chevallier, B; Fargeot, P; Metz, R; Paes, D; Pujade-Lauraine, E; Spielmann, M; Tubiana-Hulin, M | 1 |
| Adler, M; Albrecht, U; Jaenicke, F; Marschner, NW; Nagel, GA | 1 |
| Papadopoulos, I; Wand, H | 1 |
| Bonadonna, G; Bonfante, V; Brambilla, C; Crippa, F; Ferrari, L; Rossi, A; Villani, F | 1 |
| Boyd, MA; Case, DC; Ervin, TJ; Gams, R; Oldham, FB | 1 |
| Bruntsch, U; Cavalli, F; Hansen, HH; Holdener, EE; Høst, H; Pinedo, HM; Renard, J; Rozencweig, M | 1 |
| Di Pietro, N; Ganzina, F; Magni, O | 1 |
2 review(s) available for epirubicin and Vomiting
| Article | Year |
|---|---|
[Complications of hepatic artery chemotherapy for liver metastases in colorectal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arterial Occlusive Diseases; Cholangitis, Sclerosing; Cisplatin; Colorectal Neoplasms; Epirubicin; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Mitomycin; Nausea; Peptic Ulcer; Vomiting | 2003 |
Optimal control of cyclophosphamide-induced emesis.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epirubicin; Fluorouracil; Humans; Lomustine; Methotrexate; Procarbazine; Randomized Controlled Trials as Topic; Vomiting | 1996 |
43 trial(s) available for epirubicin and Vomiting
| Article | Year |
|---|---|
Mirtazapine, a dopamine receptor inhibitor, as a secondary prophylactic for delayed nausea and vomiting following highly emetogenic chemotherapy: an open label, randomized, multicenter phase III trial.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cisplatin; Cyclophosphamide; Dexamethasone; Dopamine Antagonists; Epirubicin; Female; Humans; Middle Aged; Mirtazapine; Nausea; Quality of Life; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting | 2020 |
A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophospham
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Granisetron; Humans; Middle Aged; Morpholines; Nausea; Palonosetron; Patient Reported Outcome Measures; Vomiting | 2020 |
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Epirubicin; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Thalidomide; Vomiting; Young Adult | 2017 |
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Doxorubicin; Electric Stimulation Therapy; Epirubicin; Humans; Ifosfamide; Isoquinolines; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting; Young Adult | 2014 |
[Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Neutropenia; Paclitaxel; Survival Rate; Vomiting; Young Adult | 2008 |
Omission of day 2 of antiemetic medications is a cost saving strategy for improving chemotherapy-induced nausea and vomiting control: results of a randomized phase III trial.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost Savings; Dexamethasone; Double-Blind Method; Doxorubicin; Epirubicin; Female; Humans; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Prognosis; Prospective Studies; Ranitidine; Treatment Outcome; Vomiting | 2009 |
Development of fast dissolving oral film containing dexamethasone as an antiemetic medication: clinical usefulness.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Breast Neoplasms; Cross-Over Studies; Cyclophosphamide; Dexamethasone; Dosage Forms; Drug Therapy, Combination; Epirubicin; Female; Humans; Middle Aged; Nausea; Vomiting | 2012 |
[Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Leukopenia; Middle Aged; Neoplasm Staging; Neutropenia; Premenopause; Radiotherapy, Adjuvant; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Vomiting | 2012 |
Combination of docetaxel, epirubicin and vinorelbine administered every 2 weeks as first-line therapy in patients with metastatic breast cancer: a dose-finding study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fever; Granulocyte Colony-Stimulating Factor; Humans; Middle Aged; Nausea; Neutropenia; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Vomiting | 2003 |
[Ginsenosides combined with dexamethasone in preventing and treating postembolization syndrome following transcatheter arterial chemoembolization: a randomized, controlled and double-blinded prospective trial].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Dexamethasone; Double-Blind Method; Epirubicin; Female; Fluorouracil; Ginsenosides; Humans; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Vomiting | 2005 |
Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Morpholines; Nausea; Ondansetron; Vomiting | 2005 |
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
Topics: Adolescent; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Diarrhea; Docetaxel; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Humans; Infusions, Intravenous; Middle Aged; Nausea; Neoplasm Metastasis; Neutropenia; Receptor, ErbB-2; Survival Analysis; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A; Vomiting | 2005 |
Alprazolam significantly improves the efficacy of granisetron in the prophylaxis of emesis secondary to moderately emetogenic chemotherapy in patients with breast cancer.
Topics: Alprazolam; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cross-Over Studies; Cyclophosphamide; Doxorubicin; Drug Interactions; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Granisetron; Humans; Hypnotics and Sedatives; Middle Aged; Vomiting | 2005 |
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gastrectomy; Hematologic Diseases; Humans; Immunohistochemistry; Italy; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Neoplasm Staging; Patient Compliance; Prognosis; Proportional Hazards Models; Stomach Neoplasms; Treatment Outcome; Vomiting | 2008 |
[Comparison of tolerance and toxicity of CEF-100 regimen versus CEF-60 regimen as adjuvant therapy for breast cancer].
Topics: Adult; Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Leukopenia; Middle Aged; Neutropenia; Vomiting | 2007 |
Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Breast Neoplasms; Carubicin; Daunorubicin; Doxorubicin; Drug Evaluation; Epirubicin; Female; Follow-Up Studies; Heart Diseases; Humans; Leukopenia; Middle Aged; Nausea; Neoplasm Metastasis; Random Allocation; Vomiting | 1984 |
Carboplatin in combination with epirubicin and cyclophosphamide in patients with advanced ovarian cancer. A phase II study.
Topics: Adult; Aged; Ambulatory Care; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Cyclophosphamide; Disease Progression; Epirubicin; Female; Follow-Up Studies; Humans; Laparotomy; Leukopenia; Middle Aged; Neoplasm Staging; Neoplasm, Residual; Ovarian Neoplasms; Remission Induction; Reoperation; Survival Rate; Thrombocytopenia; Vomiting | 1995 |
Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide.
Topics: Administration, Oral; Adult; Aged; Breast Neoplasms; Constipation; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Flushing; Granisetron; Headache; Humans; Injections, Intravenous; Metoclopramide; Middle Aged; Nausea; Tablets; Vomiting | 1994 |
Comparative study of the pharmacokinetics and toxicity of high-dose epirubicin with or without dexrazoxane in patients with advanced malignancy.
Topics: Adult; Aged; Drug Administration Schedule; Epirubicin; Female; Humans; Male; Middle Aged; Neoplasms; Razoxane; Stomatitis; Vomiting | 1994 |
[Clinical evaluation of granisetron hydrochloride against nausea and vomiting induced by anticancer drugs for gynecological malignant tumors].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Granisetron; Humans; Middle Aged; Nausea; Ovarian Neoplasms; Uterine Neoplasms; Vomiting | 1996 |
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Nausea; Premenopause; Regression Analysis; Survival Analysis; Vomiting | 1996 |
Chemotherapy-induced emesis: management of early and delayed emesis in milder emetogenic regimens.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Methotrexate; Metoclopramide; Ondansetron; Patient Satisfaction; Quality of Life; Surveys and Questionnaires; Vomiting | 1996 |
Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Topics: Adolescent; Adult; Aged; Antiemetics; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Cost-Benefit Analysis; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Granisetron; Granulocyte Colony-Stimulating Factor; Humans; Indoles; Injections, Intravenous; Methotrexate; Middle Aged; Ondansetron; Serotonin Antagonists; Tropisetron; Vomiting | 1996 |
5-Hydroxyindoleacetic acid excretion following combination chemotherapy with cyclophosphamide, epirubicin and 5-fluorouracil plus ondansetron compared to ondansetron alone.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Evaluation Studies as Topic; Female; Fluorouracil; Humans; Hydroxyindoleacetic Acid; Incidence; Middle Aged; Ondansetron; Selective Serotonin Reuptake Inhibitors; Vomiting | 1996 |
Delayed emesis induced by moderately emetogenic chemotherapy: do we need to treat all patients? The Italian Group for Antiemetic Research.
Topics: Acute Disease; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Granisetron; Humans; Male; Middle Aged; Neoplasms; Prognosis; Time Factors; Vomiting | 1997 |
Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic breast cancer: a pilot study.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Epirubicin; Female; Humans; Indazoles; Infusions, Intravenous; Middle Aged; Nausea; Pilot Projects; Thrombocytopenia; Treatment Outcome; Vomiting | 1998 |
[Combination effect of granisetron plus corticosteroid for prevention of cisplatin-induced emesis: a cross-over study comparing methylprednisolone and dexamethasone].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Over Studies; Dexamethasone; Drug Therapy, Combination; Endometrial Neoplasms; Epirubicin; Etoposide; Female; Granisetron; Humans; Methylprednisolone; Middle Aged; Nausea; Ovarian Neoplasms; Uterine Neoplasms; Vomiting | 1998 |
Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dopamine Antagonists; Double-Blind Method; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Glucocorticoids; Granisetron; Humans; Isonipecotic Acids; Methotrexate; Middle Aged; Nausea; Prednisolone; Serotonin Antagonists; Vomiting | 1999 |
[Usefulness of ramosetron hydrochloride on nausea and vomiting in CMF or CEF therapy for breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Appetite; Benzimidazoles; Breast Neoplasms; Breast Neoplasms, Male; Cisplatin; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Male; Methotrexate; Middle Aged; Nausea; Safety; Serotonin Antagonists; Treatment Outcome; Vomiting | 1999 |
Granisetron plus or minus alprazolam for emesis prevention in chemotherapy of lymphomas: a randomized multicenter trial. Granisetron Trialists Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alprazolam; Anti-Anxiety Agents; Antiemetics; Antineoplastic Agents; Cyclophosphamide; Dacarbazine; Doxorubicin; Epirubicin; Female; Granisetron; Humans; Lymphoma; Male; Middle Aged; Prednisone; Vomiting | 1999 |
A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
Topics: Adolescent; Adult; Aged; Alopecia; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Ifosfamide; Male; Middle Aged; Nausea; Sarcoma; Soft Tissue Neoplasms; Vomiting | 2001 |
Epirubicin: clinical toxicity during the phase II program in endometrial and cervical cancer.
Topics: Adult; Aged; Alopecia; Drug Evaluation; Endometrial Neoplasms; Epirubicin; Female; Heart; Humans; Leukopenia; Middle Aged; Spain; Uterine Cervical Neoplasms; Vomiting | 1992 |
Oral treatment with ondansetron in an outpatient setting.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Ambulatory Care; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Humans; Imidazoles; Male; Middle Aged; Nausea; Ondansetron; Serotonin Antagonists; Vomiting | 1991 |
Tetracosactrin vs. methylprednisolone in the prevention of emesis in patients receiving FEC regimen for breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cosyntropin; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Methylprednisolone; Nausea; Quality of Life; Vomiting | 1991 |
Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide.
Topics: Adult; Aged; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Imidazoles; Metoclopramide; Middle Aged; Nausea; Ondansetron; Vomiting | 1991 |
Adjuvant chemotherapy for T1-2NOMO small cell lung cancer: single-agent or combination chemotherapy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Small Cell; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Etoposide; Female; Heart Failure; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Vomiting | 1991 |
High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study.
Topics: Adult; Aged; Alopecia; Breast Neoplasms; Drug Evaluation; Epirubicin; Female; Humans; Life Tables; Middle Aged; Nausea; Survival Rate; Vomiting | 1991 |
Double-blind randomized trial of lorazepam versus placebo with methylprednisolone for control of emesis due to non-cisplatin containing chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Double-Blind Method; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Injections, Intramuscular; Injections, Intravenous; Lorazepam; Methotrexate; Methylprednisolone; Middle Aged; Vomiting | 1990 |
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Doxorubicin; Drug Administration Schedule; Epirubicin; Fluorouracil; Humans; Imidazoles; Infusions, Intravenous; Metoclopramide; Middle Aged; Nausea; Ondansetron; Randomized Controlled Trials as Topic; Time Factors; Vomiting | 1990 |
[Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Humans; Imidazoles; Metoclopramide; Neoplasm Metastasis; Ondansetron; Serotonin Antagonists; Vomiting | 1990 |
[Reducing the side effects of aggressive chemotherapy (cisplatin and epirubicin) with xenogenic peptides (factor AF2) in patients with hormone refractory metastatic prostate cancer. A prospective, randomized study].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Erythrocyte Count; Hemoglobinometry; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Peptides; Platelet Count; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Tissue Extracts; Vomiting | 1989 |
A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Nausea; Neoplasm Metastasis; Prospective Studies; Random Allocation; Vomiting | 1988 |
Phase II study of doxorubicin versus epirubicin in advanced breast cancer.
Topics: Adult; Aged; Alopecia; Breast Neoplasms; Doxorubicin; Drug Evaluation; Epirubicin; Female; Heart; Humans; Middle Aged; Mouth Diseases; Vomiting | 1986 |
23 other study(ies) available for epirubicin and Vomiting
| Article | Year |
|---|---|
Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin.
Topics: Abdominal Pain; Adult; Aged; Antibiotics, Antineoplastic; Antiemetics; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Dexamethasone; Epirubicin; Female; Gastrointestinal Diseases; Humans; Liver Neoplasms; Male; Middle Aged; Nausea; Palonosetron; Retrospective Studies; Vomiting | 2020 |
Thalidomide reduces chemotherapy-induced vomiting.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Dexamethasone; Doxorubicin; Epirubicin; Humans; Isoquinolines; Palonosetron; Quality of Life; Quinuclidines; Randomized Controlled Trials as Topic; Thalidomide; Treatment Outcome; Vomiting | 2017 |
Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Doxorubicin; Drug Therapy, Combination; Epirubicin; Female; Granisetron; Humans; Middle Aged; Nausea; Palonosetron; Prospective Studies; Vomiting | 2019 |
Single-dose palonosetron and dose-reduced regimen of dexamethasone in preventing nausea and vomiting by anthracycline-including chemotherapy in patients with early breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Isoquinolines; Middle Aged; Nausea; Neoplasm Staging; Palonosetron; Prognosis; Quinuclidines; Serotonin Antagonists; Vomiting | 2013 |
[Nausea, vomiting and quality of life in women with breast cancer receiving chemotherapy].
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Nausea; Prospective Studies; Quality of Life; Severity of Illness Index; Socioeconomic Factors; Surveys and Questionnaires; Taxoids; Trastuzumab; Vomiting | 2013 |
[Effect of dexamethasone on vascular pain caused by the administration of fosaprepitant dimeglumine and epirubicin hydrochloride in patients with primary breast cancer].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dexamethasone; Epirubicin; Humans; Middle Aged; Morpholines; Pain; Vomiting; Young Adult | 2014 |
[Predictive factors of nausea/vomiting of breast cancer patients receiving FEC and AC chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Forecasting; Humans; Male; Middle Aged; Nausea; Risk Factors; Vomiting | 2008 |
[Assessment of nausea and vomiting during FEC regimen for breast cancer after the novel antiemetic agent - introduction using MASCC antiemesis tool].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Middle Aged; Nausea; Vomiting | 2012 |
Is there an association between PONV and chemotherapy-induced nausea and vomiting?
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethasone; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease Resistance; Droperidol; Epirubicin; Female; Fluorouracil; Granisetron; Humans; Mastectomy; Methotrexate; Metoclopramide; Middle Aged; Models, Biological; Narcotics; Nausea; Ondansetron; Postoperative Nausea and Vomiting; Prospective Studies; Risk Factors; Vomiting | 2013 |
Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy.
Topics: Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Dexamethasone; Epirubicin; Female; Genotype; Humans; Nausea; Ondansetron; Polymorphism, Single Nucleotide; Receptors, Serotonin, 5-HT3; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Vomiting | 2008 |
[Effects of 4'-Epi-adriamycin, THP-adriamycin and mitoxantrone on patients with advanced and recurrent breast cancer].
Topics: Adult; Aged; Alopecia; Anthraquinones; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Middle Aged; Mitoxantrone; Nausea; Neoplasm Recurrence, Local; Vomiting | 1984 |
Phase II evaluation of 4'-epi-doxorubicin in patients with advanced colorectal carcinoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Drug Evaluation; Epirubicin; Fatigue; Humans; Leukopenia; Middle Aged; Nausea; Rectal Neoplasms; Stereoisomerism; Vomiting | 1982 |
Toxic and therapeutic activity of 4'-epi-doxorubicin.
Topics: Adolescent; Adult; Aged; Alopecia; Arrhythmias, Cardiac; Bone Marrow Diseases; Doxorubicin; Drug Evaluation; Epirubicin; Female; Heart; Humans; Male; Middle Aged; Neoplasms; Stereoisomerism; Stomatitis; Vomiting | 1982 |
[Insufficient efficacy of the use of a single 8 mg tablet of ondansetron in the prevention of nausea and vomiting induced by FEC chemotherapy].
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epirubicin; Female; Fluorouracil; Humans; Male; Nausea; Ondansetron; Tablets; Treatment Outcome; Vomiting | 1995 |
Treatment of cisplatin-related nausea and vomiting with a combination of ondansetron and metoclopramide: a pilot study.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Epirubicin; Female; Humans; Lung Neoplasms; Male; Metoclopramide; Middle Aged; Nausea; Ondansetron; Ovarian Neoplasms; Pilot Projects; Prednisolone; Uterine Neoplasms; Vinblastine; Vinorelbine; Vomiting | 1996 |
[Usefulness of continuous venous daily chemotherapy of 5-fluorouracil and low-dose cisplatin for patients undergoing noncurative surgery].
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Intravenous; Male; Middle Aged; Nausea; Ondansetron; Prognosis; Remission Induction; Vomiting | 1997 |
Tropisetron in the prevention of acute nausea and vomiting in patients treated with high dose epirubicin.
Topics: Acute Disease; Adult; Aged; Antibiotics, Antineoplastic; Antiemetics; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Constipation; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Headache; Humans; Indoles; Injections, Intravenous; Middle Aged; Nausea; Treatment Outcome; Tropisetron; Vomiting | 1998 |
Nausea and vomiting induced by arterial chemo-embolization in patients with hepatocellular carcinoma and the antiemetic effect of ondansetron hydrochloride.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antiemetics; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Eating; Epirubicin; Female; Follow-Up Studies; Humans; Incidence; Infusions, Intra-Arterial; Injections, Intra-Arterial; Iodized Oil; Liver Neoplasms; Male; Maleic Anhydrides; Middle Aged; Mitomycin; Nausea; Ondansetron; Polystyrenes; Quality of Life; Vomiting; Zinostatin | 1999 |
Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Topics: Adult; Aged; Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Dose Fractionation, Radiation; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy; Mastectomy, Modified Radical; Middle Aged; Nausea; Radiation Pneumonitis; Radiation-Protective Agents; Radiobiology; Radiodermatitis; Radiotherapy, Adjuvant; Survival Analysis; Vomiting | 2002 |
Primary chemotherapy for locally advanced uterine cervical carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Humans; Middle Aged; Nausea; Survival Rate; Uterine Cervical Neoplasms; Vomiting | 1992 |
Phase I-II trial of high-dose epirubicin in patients with lymphoma.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Bone Marrow; Doxorubicin; Drug Evaluation; Epirubicin; Fever; Humans; Lymphoma; Middle Aged; Nausea; Stomatitis; Vomiting | 1987 |
Epirubicin in colorectal cancer. A phase II study of the early clinical trials group (EORTC).
Topics: Adult; Aged; Alopecia; Antibiotics, Antineoplastic; Colonic Neoplasms; Doxorubicin; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Humans; Injections, Intravenous; Leukopenia; Male; Middle Aged; Rectal Neoplasms; Vomiting | 1985 |
Clinical toxicity of 4'-epi-doxorubicin (epirubicin).
Topics: Alopecia; Bone Marrow; Breast Neoplasms; Doxorubicin; Epirubicin; Heart; Heart Diseases; Humans; Nausea; Vomiting | 1985 |